{
    "nctId": "NCT03590938",
    "briefTitle": "Lynparza Breast Cancer Clinical Experience Investigation",
    "officialTitle": "Lynparza Tablets 100mg, 150mg CEI, Investigation on Development of Bone Marrow Depression in Patients With Unresectable or Recurrent BRCA Mutated HER2 Negative Breast Cancer Who Have Previously Received Anticancer Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 111,
    "primaryOutcomeMeasure": "Adverse drug reactions of bone marrow depression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Unresectable or recurrent BRCA mutated HER2 negative breast cancer with prior anticancer chemotherapy\n\nExclusion Criteria:\n\n* The patients who are not started on Lymparza for the first time",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}